Potential conflicts of interest . V. G. F. reports personal fees from Novartis, Novadigm, Durata, Debiopharm, Genentech, Achaogen, Affinium, Medicines Co., Cerexa, Tetraphase, Trius, MedImmune, Bayer, Theravance, Basilea, Affinergy, Janssen, xBiotech, Contrafect, Regeneron, Basilea, Destiny, Amphliphi Biosciences, Integrated Biotherapeutics, C3J, Armata, Valanbio, Akagera, Aridis, Roche, Pfizer. Grants from NIH, MedImmune, Allergan, Pfizer, Advanced Liquid Logics, Theravance, Novartis, Merck, Medical Biosurfaces, Locus, Affinergy, Contrafect, Karius, Genentech, Regeneron, Basilea, Janssen, and Akagera. Royalties from UpToDate; stock options from Valanbio and ArcBio; a patent sepsis diagnostics pending; and a stipend from Infectious Diseases Society of America for service as Associate Editor on Clinical Infectious Diseases (2017–2022). Support from Contrafect to present Phase 2 data at 2019 ECCMID. J. M. M. has received consulting honoraria and/or research grants from AbbVie, Angelini, Contrafect, Cubist, Genentech, Gilead Sciences, Jansen, Lysovant, Medtronic, MSD, Novartis, Pfizer, and ViiV Healthcare. J. M. M. received a personal 80:20 research grant from Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, during 2017–2021. N. E. B. has received an unrestricted research grant from the Novo Nordisk Foundation, not related to this article. N. E. B. also reports research grants not related to this study and paid to institution from Health Insurance Denmark, Augustinus Foundation, Kaj Hansen Foundation; and participation in the DSMB for the Danish Heart Runner Project. The other author reports no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.